Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia
- PMID: 7561817
Alcohol, cannabis, nicotine, and caffeine use and symptom distress in schizophrenia
Abstract
The high prevalence of substance use, e.g., alcohol and illegal and nonprescribed drugs, in schizophrenia is widely recognized. One explanation for this high prevalence is that substance use may be a self-initiated method for managing symptoms. To test whether the intake of four substances--alcohol, cannabis, nicotine, and caffeine--would increase with increases in symptom distress, daily self-reports of symptom distress and substance intake over 12 weeks were analyzed with pooled time series analyses. Compliance with neuroleptic medication was added to the analyses to control for any changes in prescribed medication compliance while using nonprescribed drugs or alcohol. Of the four substances studied, only nicotine was significantly related to symptom distress. Higher distress with prodromal symptoms was related to decreases in nicotine use. Analysis of caffeine did not meet the criteria for significance but does provide direction for further research. Higher distress, with neurotic symptoms, was related to increases in caffeine use. Further research is needed to clarify the relationship between nicotine and symptoms.
Similar articles
-
Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial.Curr Med Res Opin. 2006 Jul;22(7):1277-85. doi: 10.1185/030079906X112561. Curr Med Res Opin. 2006. PMID: 16834826
-
Specificity of genetic and environmental risk factors for symptoms of cannabis, cocaine, alcohol, caffeine, and nicotine dependence.Arch Gen Psychiatry. 2007 Nov;64(11):1313-20. doi: 10.1001/archpsyc.64.11.1313. Arch Gen Psychiatry. 2007. PMID: 17984400
-
[Schizophrenia and addiction: An evaluation of the self-medication hypothesis].Encephale. 2003 May-Jun;29(3 Pt 1):193-203. Encephale. 2003. PMID: 12876543 Review. French.
-
Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse.Neurosci Lett. 2006 Jun 12;400(3):262-6. doi: 10.1016/j.neulet.2006.02.056. Epub 2006 Mar 15. Neurosci Lett. 2006. PMID: 16540246 Clinical Trial.
-
Comorbid substance use disorder in schizophrenia: a selective overview of neurobiological and cognitive underpinnings.Psychiatry Clin Neurosci. 2013 Sep;67(6):367-83. doi: 10.1111/pcn.12072. Epub 2013 Jul 25. Psychiatry Clin Neurosci. 2013. PMID: 23890122 Review.
Cited by
-
Defining and assessing adherence to oral antipsychotics: a review of the literature.Schizophr Bull. 2006 Oct;32(4):724-42. doi: 10.1093/schbul/sbj075. Epub 2006 May 17. Schizophr Bull. 2006. PMID: 16707778 Free PMC article. Review.
-
Cannabis and psychopathology : update 2004.Indian J Psychiatry. 2004 Oct;46(4):299-309. Indian J Psychiatry. 2004. PMID: 21206788 Free PMC article.
-
Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus.Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):587-92. doi: 10.1073/pnas.94.2.587. Proc Natl Acad Sci U S A. 1997. PMID: 9012828 Free PMC article.
-
Patterns of Caffeine Use and Validation of Assessment in Psychiatric Population: An Implication in Primary Care Setting.J Family Med Prim Care. 2020 Oct 30;9(10):5252-5255. doi: 10.4103/jfmpc.jfmpc_698_20. eCollection 2020 Oct. J Family Med Prim Care. 2020. PMID: 33409197 Free PMC article.
-
Impact of substance use disorder on presentation and short-term course of schizophrenia.Psychiatry J. 2014;2014:280243. doi: 10.1155/2014/280243. Epub 2014 Apr 2. Psychiatry J. 2014. PMID: 24839596 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical